Do glucagon-like peptide 1 analogues (GLP-1) improve patient-oriented outcomes in type 2 diabetes?
Compared to placebo^ semaglutide and liraglutide^ but not lixisenatide^ reduce cardiovascular disease (CVD) for ~1 in 50 diabetics with existing CVD over 2-4 years^ irrespective of specific A1c targets (attaining ~7.5%). These drugs reduce weight 0.7-4.3 kg^ but around one in 25 more than placebo will stop due to gastrointestinal effects. Some uncertainty around neoplasm risk remains.
Publication Date: 2017-2-6
Last Updated on PCR: 2017-03-31 14:13:27